PLAUR and cancer: The high-affinity binding moiety AE105 has also successfully been utilized in the development of uPAR-targeted PET imaging agents where phase II clinical trials in different types of cancer, including head and neck squamous cell carcinoma (HNSCC), have been conducted 22,27-29.